Resposta patológica completa e prognóstico após QT Neo + terapia anti-HER2 no câncer de mama inicial HER2+

Notas do episódio

Referências: van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE Jr, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Squifflet P, Saad ED, Heinzmann D, Denkert C, Rastogi P, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. J Clin Oncol. 2023 Apr 19:JCO2202241. doi: 10.1200/JCO.22.02241. Epub ahead of print. PMID: 37075276. https://ascopubs.org/doi/abs/10.1200/JCO.22.02241 __